Detalhe da pesquisa
1.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272527
2.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Blood
; 143(6): 496-506, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879047
3.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
4.
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Blood
; 142(26): 2327-2331, 2023 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738563
5.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 23(1): 91-103, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895487
6.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32688395
7.
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Haematologica
; 106(7): 1932-1942, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538152
8.
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Curr Treat Options Oncol
; 22(12): 111, 2021 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34694508
9.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer
; 126(2): 293-303, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31568564
10.
Refining the management of relapsed or refractory follicular lymphoma.
Clin Adv Hematol Oncol
; 18 Suppl 20(12): 1-24, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843893
11.
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Blood
; 138(18): 1768-1773, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34297826
12.
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.
Haematologica
; 106(1): 284-287, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32079693
13.
Clinical use of emerging therapies in relapsed or refractory follicular lymphoma.
Clin Adv Hematol Oncol
; 18 Suppl 20(12): 15-19, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843896
14.
Refining the management of relapsed or refractory follicular lymphoma: case scenarios.
Clin Adv Hematol Oncol
; 18 Suppl 20(12): 20-21, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843897
15.
How often do hematologists consider celiac disease in iron-deficiency anemia? Results of a national survey.
Clin Adv Hematol Oncol
; 12(2): 100-5, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24892255
16.
Radon-222 and Leukemia.
Health Phys
; 124(6): 475-477, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36880974
17.
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Leuk Lymphoma
; 64(14): 2225-2235, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740588
18.
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Clin Cancer Res
; 29(10): 1894-1905, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999993
19.
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Blood Adv
; 7(18): 5579-5585, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37522731
20.
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Clin Lymphoma Myeloma Leuk
; 23(7): 515-526, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37076367